Literature DB >> 24795457

Structural and functional correlates of enhanced antiviral immunity generated by heteroclitic CD8 T cell epitopes.

Jonathan A Trujillo1, Stephanie Gras2, Kelly-Anne Twist2, Nathan P Croft2, Rudragouda Channappanavar3, Jamie Rossjohn4, Anthony W Purcell2, Stanley Perlman5.   

Abstract

Peptides that bind poorly to MHC class I molecules often elicit low-functional avidity T cell responses. Peptide modification by altering the anchor residue facilitates increased binding affinity and may elicit T cells with increased functional avidity toward the native epitope ("heteroclitic"). This augmented MHC binding is likely to increase the half-life and surface density of the heteroclitic complex, but precisely how this enhanced T cell response occurs in vivo is not known. Furthermore, the ideal heteroclitic epitope will elicit T cell responses that completely cross-react with the native epitope, maximizing protection and minimizing undesirable off-target effects. Such epitopes have been difficult to identify. In this study, using mice infected with a murine coronavirus that encodes epitopes that elicit high (S510, CSLWNGPHL)- and low (S598, RCQIFANI)-functional avidity responses, we show that increased expression of peptide S598 but not S510 generated T cells with enhanced functional avidity. Thus, immune responses can be augmented toward T cell epitopes with low functional avidity by increasing Ag density. We also identified a heteroclitic epitope (RCVIFANI) that elicited a T cell response with nearly complete cross-reactivity with native epitope and demonstrated increased MHC/peptide abundance compared with native S598. Structural and thermal melt analyses indicated that the Q600V substitution enhanced stability of the peptide/MHC complex without greatly altering the antigenic surface, resulting in highly cross-reactive T cell responses. Our data highlight that increased peptide/MHC complex display contributes to heteroclitic epitope efficacy and describe parameters for maximizing immune responses that cross-react with the native epitope.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24795457      PMCID: PMC4052115          DOI: 10.4049/jimmunol.1400111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

2.  T cell allorecognition via molecular mimicry.

Authors:  Whitney A Macdonald; Zhenjun Chen; Stephanie Gras; Julia K Archbold; Fleur E Tynan; Craig S Clements; Mandvi Bharadwaj; Lars Kjer-Nielsen; Philippa M Saunders; Matthew C J Wilce; Fran Crawford; Brian Stadinsky; David Jackson; Andrew G Brooks; Anthony W Purcell; John W Kappler; Scott R Burrows; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

3.  Integration, scaling, space-group assignment and post-refinement.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 5.  Design of multi-epitope, analogue-based cancer vaccines.

Authors:  John D Fikes; Alessandro Sette
Journal:  Expert Opin Biol Ther       Date:  2003-09       Impact factor: 4.388

6.  Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen.

Authors:  Daniel E Speiser; Petra Baumgaertner; Verena Voelter; Estelle Devevre; Catherine Barbey; Nathalie Rufer; Pedro Romero
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-04       Impact factor: 11.205

7.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

8.  Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope.

Authors:  Alex T Chen; Markus Cornberg; Stephanie Gras; Carole Guillonneau; Jamie Rossjohn; Andrew Trees; Sebastien Emonet; Juan C de la Torre; Raymond M Welsh; Liisa K Selin
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

9.  Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

Authors:  Jorge R Almeida; David A Price; Laura Papagno; Zaïna Aït Arkoub; Delphine Sauce; Ethan Bornstein; Tedi E Asher; Assia Samri; Aurélie Schnuriger; Ioannis Theodorou; Dominique Costagliola; Christine Rouzioux; Henri Agut; Anne-Geneviève Marcelin; Daniel Douek; Brigitte Autran; Victor Appay
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

10.  Heteroclitic immunization induces tumor immunity.

Authors:  R Dyall; W B Bowne; L W Weber; J LeMaoult; P Szabo; Y Moroi; G Piskun; J J Lewis; A N Houghton; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  8 in total

1.  The cellular redox environment alters antigen presentation.

Authors:  Jonathan A Trujillo; Nathan P Croft; Nadine L Dudek; Rudragouda Channappanavar; Alex Theodossis; Andrew I Webb; Michelle A Dunstone; Patricia T Illing; Noah S Butler; Craig Fett; David C Tscharke; Jamie Rossjohn; Stanley Perlman; Anthony W Purcell
Journal:  J Biol Chem       Date:  2014-08-18       Impact factor: 5.157

2.  Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination.

Authors:  Adil Doganay Duru; Renhua Sun; Eva B Allerbring; Jesseka Chadderton; Nadir Kadri; Xiao Han; Kaliroi Peqini; Hannes Uchtenhagen; Chaithanya Madhurantakam; Sara Pellegrino; Tatyana Sandalova; Per-Åke Nygren; Stephen J Turner; Adnane Achour
Journal:  PLoS Pathog       Date:  2020-05-04       Impact factor: 6.823

Review 3.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.

Authors:  William J Liu; Min Zhao; Kefang Liu; Kun Xu; Gary Wong; Wenjie Tan; George F Gao
Journal:  Antiviral Res       Date:  2016-11-11       Impact factor: 5.970

Review 4.  Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides.

Authors:  Adeolu Oyemade Adegoke; Michael David Grant
Journal:  Front Immunol       Date:  2015-07-23       Impact factor: 7.561

5.  Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance.

Authors:  Sietske K Rosendahl Huber; Jolien J Luimstra; Josine van Beek; Rieuwert Hoppes; Ronald H J Jacobi; Marion Hendriks; Kim Kapteijn; Casper Ouwerkerk; Boris Rodenko; Huib Ovaa; Jørgen de Jonge
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

6.  HLA-G peptide preferences change in transformed cells: impact on the binding motif.

Authors:  Alexander A Celik; Gwendolin S Simper; Wiebke Hiemisch; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2018-03-30       Impact factor: 2.846

7.  Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice.

Authors:  YongLi Hou; Ting Yan; Hui Cao; Peng Liu; Kang Zheng; Zhenyu Li; Qing Deng; SiHai Hu
Journal:  Int J Nanomedicine       Date:  2019-08-16

8.  SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship.

Authors:  Volodymyr V Oberemok; Kateryna V Laikova; Kseniya A Yurchenko; Irina I Fomochkina; Anatolii V Kubyshkin
Journal:  Inflamm Res       Date:  2020-04-30       Impact factor: 6.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.